Relapsed/Refractory

The term “relapsed” refers to disease that reappears or grows again after a period of remission. The term “refractory” is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long.

Similar to the first-line setting, standard treatment for relapsed/refractory ATLL has not been established. Many chemotherapy regimens used to treat other T-cell lymphomas following a relapse are also being used to treat ALL, including the following:

• DHAP (dexamethasone, cytarabine, and cisplatin)
• ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin)
• GDP (gemcitabine, dexamethasone, and cisplatin)
• ICE (ifosfamide, carboplatin, and etoposide)
• Pralatrexate (Folotyn)
• Belinostat (Beleodaq).

Learn More

To learn more about ATLL, download the T-Cell Lymphomas Guide Want to talk to someone? For answers to lymphoma-related questions 
and resources, contact our Lymphoma Resource Center at (800) 500-9976 or [email protected].